2019 年第一季度报告 公司代码：603880 公司简称：南卫股份 江苏南方卫材医药股份有限公司 2019 年第一季度报告 1 / 19 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 8 | 2019 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度 | | | --- | --- | --- | --- | --- | | | | | 末增减(%) | | | 总资产 | 851,964,048.93 | 845,813,968.47 | | 0.73 | | 归属于上市公司股东的 | 566,027,323.78 | 556,725,473.98 | | 1.67 | | 净资产 | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | | 经营活动产生的现金流 | 11,284,653.07 | 9,492,642.49 | | 18.88 | | 量 ...

2018 年年度报告 公司代码：603880 公司简称：南卫股份 江苏南方卫材医药股份有限公司 2018 年年度报告 1 / 197 2018 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法 律责任。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 公司拟以2018年12月31日公司总股本13,000万股为基数，向全体股东每10股派发 现金红利人民币1.6元（含税），共计派发现金红利2,080万元；同时以资本公积转增 股本方式向全体股东每10股转增3股，合计转增3900万股，转增后公司总股本将增加 至16,900万股。 以上利润分配预案尚需公司2018年年度股东大会审议通过。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质 承诺，请投资者注意风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 报告期内，不存在对公司生 ...

2018 年第三季度报告 公司代码：603880 公司简称：南卫股份 江苏南方卫材医药股份有限公司 2018 年第三季度报告 1 / 21 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 7 | | 四、 | 附录 | 9 | 2018 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人李平、主管会计工作负责人项琴华及会计机构负责人（会计主管人员）王亚华保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | | 本报告期末比上年 度末增减(%) | | --- | --- | --- | --- | --- | | 总资产 | 842,849,977.1 ...

Financial Performance - The company's operating revenue for the first half of 2018 was ¥230,793,324.29, a decrease of 3.91% compared to ¥240,192,092.11 in the same period last year[18]. - The net profit attributable to shareholders of the listed company increased by 38.16% to ¥38,445,555.64, up from ¥27,826,528.14 in the previous year[18]. - The net cash flow from operating activities was ¥29,989,139.78, down 15.61% from ¥35,537,276.54 in the same period last year[18]. - Basic earnings per share decreased by 18.92% to ¥0.30 from ¥0.37 in the same period last year[19]. - The weighted average return on net assets decreased by 3.45 percentage points to 6.98% from 10.43% in the previous year[19]. - The company reported a decrease of 54.05% in basic earnings per share after deducting non-recurring gains and losses, down to ¥0.17 from ¥0.37[19]. - The company reported a total of CNY 108,268,452.35 in inventory, up from CNY 105,471,996.88, which is an increase of approximately 2.7%[113]. - The company’s net profit margin for the first half of 2018 was approximately 0.16% based on the reported net profit and total assets[62]. - The company reported a comprehensive income total of 36,936,215.00 RMB during the first half of the year, indicating positive financial performance[137]. Assets and Liabilities - The total assets at the end of the reporting period were ¥843,419,013.64, an increase of 2.49% from ¥822,964,834.25 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company increased by 4.50% to ¥555,759,443.37 from ¥531,813,887.73 at the end of the previous year[18]. - Accounts receivable increased by 35.11% to RMB 21,779,325.10, primarily due to an increase in customer notes[51]. - Other receivables surged by 1,536.4% to RMB 65,556,293.67, mainly from government land receipts[51]. - Total liabilities for accounts payable rose by 175.00% to RMB 27,500,000.00, mainly due to increased procurement of raw materials[51]. - The company's total liabilities decreased from CNY 285,396,035.23 to CNY 282,112,934.51, a reduction of approximately 1.1%[114]. - The company's equity attributable to shareholders increased from CNY 531,813,887.73 to CNY 555,759,443.37, marking an increase of about 4.5%[115]. - The total equity attributable to the parent company at the end of the reporting period is 536,786,370.00 RMB, compared to 256,685,005.00 RMB at the end of the previous year, reflecting a significant increase[134]. Operational Strategy - The company operates in the pharmaceutical manufacturing industry, focusing on transdermal products, medical adhesive tapes, bandages, and emergency kits, with a product line that includes various types of band-aids and protective products[24]. - The procurement model is based on "sales-driven purchasing," where raw materials are procured according to customer orders, ensuring efficient inventory management[26]. - The production model follows an "order-based production" approach, allowing the company to adapt to customer needs and maintain production efficiency[26]. - The company has strengthened its focus on developing its own brand products, particularly in emergency kits and sports protection products, alongside its existing partnerships[28]. - The sales strategy includes both ODM (Original Design Manufacturer) and direct sales to enhance market presence and brand recognition[28]. - The company aims to expand its market reach by increasing the development of self-branded products and enhancing its sales capabilities in both domestic and international markets[28]. Research and Development - The company has established a strong technical research and development advantage, focusing on various advanced technologies, including high-water-absorption hydrogel preparation and EVA film wound dressing technology[36]. - The company has developed new high-end functional dressings, including chitosan and alginate wound dressings, enhancing its product line and expected profitability[37]. - The company collaborates with major research institutions to enhance its R&D capabilities, including partnerships with Zhejiang University and Nanjing University of Technology[36]. Market Environment - The medical device industry in China is experiencing rapid growth, with the revenue growth rate of major manufacturing enterprises ranging from 11.66% to 22.20%, significantly outpacing the overall economic growth rate[31]. - The global market for bandages and medical dressings is projected to reach $24.4 billion by 2020 and $31.3 billion by 2025, indicating strong demand for medical dressings regardless of economic conditions[33]. - The demand for high-end medical dressings is expected to grow, driven by their ability to shorten healing times and reduce nursing care time, leading to a shift in market share from traditional to advanced products[33]. Corporate Governance - The company did not propose any profit distribution or capital reserve fund transfer for the half-year period, with no dividends or stock bonuses planned[67]. - The actual controller and shareholders committed to not transferring or managing their shares for 36 months post-IPO, with additional commitments from other shareholders for 12 months[69]. - The company guarantees that its prospectus does not contain false records, misleading statements, or major omissions, and will take responsibility for its accuracy[80]. - The company and its major stakeholders commit to compensating investors for losses caused by any false records or misleading statements in the prospectus[81]. Environmental Compliance - The company implemented clean production processes and maintained compliance with national environmental standards, achieving standard emissions for wastewater and waste gas[92]. - The company has established an emergency response plan for environmental incidents and conducted training to enhance its emergency handling capabilities[92]. - The company has not reported any environmental pollution incidents during the reporting period[92]. Shareholder Information - The largest shareholder, Li Ping, holds 57,817,500 shares, representing 44.4% of the total shares[101]. - The second-largest shareholder, Suzhou Lanying Investment Partnership, holds 11,700,000 shares, representing 9.00% of the total shares[101]. - The company plans to distribute a cash dividend of RMB 1.45 per 10 shares, totaling RMB 14.5 million, and to increase its total share capital by 30 million shares through capital reserve conversion[97].

Financial Performance - Operating revenue for the period was CNY 119,120,407.54, an increase of 12.65% year-on-year[6] - Net profit attributable to shareholders was CNY 12,204,399.33, reflecting a growth of 5.39% compared to the same period last year[6] - The net profit after deducting non-recurring gains was CNY 11,216,580.53, a slight increase of 0.49% year-on-year[6] - Net profit for Q1 2018 reached CNY 12,053,115.04, representing a 4.0% increase from CNY 11,590,253.99 in Q1 2017[25] - The net profit for Q1 2018 was CNY 9,639,797.83, a decrease of 21.5% compared to CNY 12,220,720.72 in the same period last year[28] - Operating profit for Q1 2018 was CNY 10,891,919.31, down 20.9% from CNY 13,761,987.04 in Q1 2017[28] Cash Flow - The net cash flow from operating activities was CNY 9,492,642.49, down 45.28% from CNY 17,348,204.80 in the previous year[6] - Cash flow from operating activities decreased by 45.28% to ¥9,492,642.49, mainly due to reduced sales collections[15] - Cash flow from operating activities generated a net amount of CNY 9,492,642.49, a decline of 45.2% compared to CNY 17,348,204.80 in the previous year[30] - Total cash inflow from operating activities was CNY 81,031,119.72, down 11.2% from CNY 91,268,288.75 in Q1 2017[30] - Cash outflow from operating activities totaled CNY 71,538,477.23, a decrease of 3.2% compared to CNY 73,920,083.95 in the same period last year[30] - The company reported a cash flow from investing activities net outflow of CNY 36,281,591.18, worsening from a net outflow of CNY 5,771,057.98 in Q1 2017[31] - Cash flow from financing activities showed a net outflow of CNY 45,494,049.14, compared to a net inflow of CNY 4,605,660.36 in the previous year[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 800,290,545.30, a decrease of 2.76% compared to the end of the previous year[6] - Total assets decreased to ¥800,290,545.30 from ¥822,964,834.25, reflecting a decline in overall asset value[18] - Total liabilities for Q1 2018 were CNY 245,764,875.82, a decrease of 2.0% from CNY 252,218,729.28 in the previous year[22] - The company's total equity increased to CNY 546,426,175.23, compared to CNY 536,786,377.40 in the same period last year, reflecting a growth of 1.2%[22] Shareholder Information - The total number of shareholders at the end of the reporting period was 10,557[11] - The largest shareholder, Li Ping, held 44.48% of the shares, with 19,148,600 shares pledged[11] Earnings and Expenses - Basic earnings per share were CNY 0.12, a decrease of 20.00% from CNY 0.15 in the previous year[6] - Earnings per share for Q1 2018 were CNY 0.12, down from CNY 0.15 in the previous year[26] - The company reported a financial expense of CNY 5,177,783.59 in Q1 2018, significantly higher than CNY 1,836,114.57 in Q1 2017[25] - Financial expenses surged by 182.00% to ¥5,177,783.59, primarily attributed to fluctuations in the USD exchange rate[15] Other Financial Metrics - The company recognized non-recurring gains of CNY 987,818.80 during the reporting period[10] - Other receivables decreased by 49.82% to ¥2,010,008.90, primarily due to export tax rebates and intercompany transactions[15] - Other current assets increased by 31.28% to ¥83,799,862.05, mainly due to the purchase of financial products[15] - Employee compensation payable decreased by 47.77% to ¥4,120,558.63, mainly due to salary disbursements[15] - Accounts payable increased by 125.00% to ¥22,500,000.00, primarily due to increased procurement of raw materials[15] - Inventory decreased to ¥98,951,234.38 from ¥105,471,996.88, indicating a reduction in stock levels[17] - The company's long-term equity investments increased to CNY 130,753,850.70 from CNY 100,814,145.20 year-over-year, marking a growth of 29.7%[22] Cash and Cash Equivalents - The ending cash and cash equivalents balance was CNY 182,292,092.45, down from CNY 258,328,947.83 at the beginning of the period[31] - Total cash and cash equivalents decreased by $76.67 million during the period[33] - The ending balance of cash and cash equivalents was $134.79 million, down from $88.10 million last year[33]

Financial Performance - The company's operating revenue for 2017 was RMB 488.71 million, representing a 10.01% increase compared to RMB 444.24 million in 2016[21] - The net profit attributable to shareholders of the listed company decreased by 8.42% to RMB 47.60 million in 2017 from RMB 51.98 million in 2016[21] - The net profit after deducting non-recurring gains and losses was RMB 45.38 million, down 11.00% from RMB 50.99 million in the previous year[21] - The net cash flow from operating activities was RMB 49.24 million, a significant decrease of 50.44% compared to RMB 99.35 million in 2016[21] - Basic earnings per share decreased by 17.39% to CNY 0.57 compared to the previous year[22] - The weighted average return on equity dropped by 7.92 percentage points to 13.14%[22] - The gross profit margin for the industrial segment was 26.43%, a decrease of 3.17 percentage points compared to the previous year[57] - The company reported a net cash flow from financing activities increased significantly to ¥216,807,123.25, driven by the initial public offering[69] - The company achieved operating revenue of RMB 488.71 million, an increase of RMB 44.47 million or 10.01% compared to the previous year[51] - The net profit attributable to shareholders decreased by RMB 4.38 million, down 8.42% year-on-year, totaling RMB 47.60 million[51] Assets and Liabilities - The total assets of the company increased by 59.32% to RMB 822.96 million at the end of 2017, up from RMB 516.55 million at the end of 2016[21] - The net assets attributable to shareholders of the listed company rose by 110.24% to RMB 531.81 million at the end of 2017, compared to RMB 252.96 million at the end of 2016[21] - Total liabilities rose from RMB 259.87 million to RMB 285.40 million, resulting in a decrease in the debt-to-asset ratio from 50.31% to 34.68%[175] - The company’s accounts payable increased by 56.01% to RMB 88,742,453.98, reflecting higher purchase volumes[72] - Monetary funds rose by 174.29% to RMB 268,328,947.84, attributed to stock issuance and inventory increases[72] Market and Industry Insights - The medical device market in China is projected to exceed RMB 700 billion by 2020, with an annual growth rate of over 10% expected in the next decade[35] - The medical device industry in China saw a revenue growth rate of over 10% from 2010 to 2015, with 2015 revenue reaching RMB 241.4 billion, a year-on-year increase of 13%[36] - The medical dressing market in China has an annual output value of RMB 30 billion, growing at a rate of 20%-30% per year[76] - The wound care market in China is experiencing growth, with a significant increase in demand for advanced wound dressings that can shorten healing time and improve patient comfort[77] - The domestic market for topical analgesic patches is rapidly expanding, driven by a large patient population suffering from musculoskeletal pain, with over 200 manufacturers currently producing various types of patches[79] Research and Development - The company emphasizes technological research and development, achieving leading positions in various technologies such as high water absorption hydrogel preparation and EVA film wound dressing technology[39] - The company has developed high-end functional dressings and emergency kits, enhancing its product line and expected profitability[40] - The company has invested heavily in R&D, focusing on improving production efficiency and product quality, with significant advancements in high-speed adhesive plaster machines and automatic equipment for medical tape production[90] - The company’s research and development expenses amounted to RMB 19.91 million, reflecting a 5.79% increase year-on-year[54] - Major R&D projects include the development of a new type of transdermal patch with a cumulative investment of ¥3,900,000 and a solvent-free adhesive patch with ¥10,372,988.78 invested[96] Product and Market Strategy - The company primarily engages in the research, production, and sales of transdermal products, medical adhesive tapes, and emergency kits[28] - The company’s main products include band-aids, medical tapes, and sports protection products, with a focus on innovation in transdermal delivery systems[28] - The company primarily operates under the ODM model and is increasing efforts in developing its own brand products, focusing on first aid kits, sports protection products, and nursing products[32] - The company has established partnerships with several hospitals and pharmaceutical groups in China, enhancing its sales network across regions such as Beijing, Shandong, and Zhejiang[49] - The company plans to enhance R&D efficiency and reduce risks by integrating its technological and industrial resources, collaborating with universities and research institutions[92] Shareholder and Governance - The company has established a differentiated cash dividend policy, ensuring that cash dividends account for at least 25% of distributable profits when conditions allow[125] - The profit distribution plan for 2017 is subject to approval at the annual shareholders' meeting[131] - The company has committed to protecting the rights of minority shareholders during the profit distribution process[128] - The controlling shareholder, Li Ping, committed to vote in favor of the company's share repurchase plan at the upcoming shareholders' meeting[136] - The company guarantees the authenticity, accuracy, and completeness of its IPO documents, with legal responsibility for any misrepresentation[143] Operational Efficiency - The company has implemented a cost control system across procurement, production, sales, logistics, and after-sales service, effectively reducing production costs and improving profitability[45] - The company has improved production automation and introduced advanced equipment, resulting in increased production efficiency and product quality, particularly in the adhesive bandage and ointment sectors[46] - The company has established a strong management team with extensive experience, ensuring effective governance and operational management[42] - The company has established a comprehensive training management system to ensure effective training outcomes[200] - The company emphasizes a performance-linked compensation structure, aligning salaries with profitability and promoting value creation[199] Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[191] - New product launches are expected to contribute an additional 200 million in revenue in the upcoming year[191] - The company plans to enhance its production capacity with the new medical adhesive dressing project, targeting an annual production capacity of 3 billion adhesive bandages and 2.6 million square meters of medical adhesive tape[116] - The company is considering strategic acquisitions to enhance its market position, with a target of identifying at least two potential candidates[191] - The company aims to achieve a revenue target of 500 million yuan and a net profit of 49 million yuan for the year 2018[115]

2017 年第三季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | | 上年度末 | | 本报告期末比上年 度末增减(%) | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 总资产 | 799,173,598.07 | | 516,552,378.80 | | 54.71 | | | | 归属于上市公司股东的净资产 | 525,329,664.32 | | 252,958,457.33 | | 107.67 | | | | | 年初至报告期末 | | 上年初至上年报告 | | 比上年同期增减(%) | | | | | （1-9 | 月） | 期末（1-9 | 月） | | | | | 经营活动产生的现金流量净额 | 45,644,548.08 | | 56,410,301.72 | | -19.08 | | | | | 年初至报告期末 | | 上年初至上年报告 | | 比上年同期增减 | | | | | （1-9 | 月） | 期末（1-9 | 月） | （%） | | | | 营 ...